ArticleOncotarget2020

Anti-tumor activities of the new oral pan-RAF inhibitor, TAK-580, used as monotherapy or in combination with novel agents in multiple myeloma.

Rikio Suzuki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.